Abstract: In a method for the precipitation of particles of a metal carbonate material comprising nickel and manganese in an atomic ratio of 0?Ni:Mn?1:3, aqueous solutions comprising sulfates or nitrates of nickel and manganese are mixed with aqueous solutions of carbonates or mixtures of carbonates and hydroxides of sodium or potassium in a stirred reactor at pH>7.5 without the use of a chelating agent. Thereby agglomerated particles are formed without any subsequent process steps, in particular no subsequent process at temperatures higher than the precipitation temperature.

Abstract: The present disclosure involves optimized methods for production of biologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.

Abstract: An ostomy appliance has a waste collection bag attached to an adhesive wafer. The adhesive wafer includes an adhesive layer, a backing layer deposited on a distal side of the adhesive layer, a hole formed through the adhesive layer, and a neutralizing layer deposited on the distal side of the adhesive layer. The neutralizing layer is in direct contact with the adhesive layer and is inside of the waste collection bag. The neutralizing layer has a neutralizer that is adapted to neutralize output from the stoma.

Abstract: The present disclosure provides ACE2-Fc fusion proteins comprising an ACE2 extracellular domain or fragment thereof and one or more Fc domains and methods of use thereof.

Abstract: The present disclosure provides methods of treating and/or preventing viral infections comprising administering ACE2-Fc fusion proteins in combination with a second therapeutic agent, such as a monoclonal antibody.

Abstract: Disclosed is a complementary-material element (22) attachable to a base plate (24) of an ostomy appliance (20) and including a first entity (30) and a second entity (32). The entities comprise different material compositions. The material composition of the second entity comprises a neutralizer which is released from the complementary-material element in response to moisture, thereby neutralizing the damaging effects of stomal output.

Abstract: An ostomy appliance has a waste collection bag attached to an adhesive wafer. The adhesive wafer includes an adhesive layer, a backing layer deposited on a distal side of the adhesive layer, a hole formed through the adhesive layer, and a neutralizing layer deposited on the distal side of the adhesive layer. The neutralizing layer is in direct contact with the adhesive layer and is inside of the waste collection bag. The neutralizing layer has a neutralizer that is adapted to neutralize output from the stoma.

Abstract: An adhesive wafer for an ostomy device, the wafer comprising a skin-facing adhesive layer, a backing layer on a part of the non-skin-facing side of the adhesive layer, and a hole for accommodating a stoma. On the central portion of the wafer is located a release layer being configured to release a neutralizer. The release layer is in direct contact with the adhesive layer. The neutralizer is capable of neutralizing or at least minimizing the level of skin or adhesive aggressiveness of the output.

Abstract: The present invention provides methods for the identification of patients with an inflammatory or autoimmune disease that demonstrate an inadequate response to treatment with a multi-Fc therapeutic, and the determination of an optimal dose of a multi-Fc therapeutic for said patient based on the patient's circulating levels of inactivated C3b (iC3b) and/or additional complement components that may be employed as a surrogate for iC3b based on an analogous response to multi-Fc therapeutics.

Abstract: The present disclosure involves optimized methods for production of biologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.

Abstract: The present invention provides methods for the identification of patients with an inflammatory or autoimmune disease that demonstrate an inadequate response to treatment with a multi-Fc therapeutic, and the determination of an optimal dose of a multi-Fc therapeutic for said patient based on the patient's circulating levels of inactivated C3b (iC3b) and/or additional complement components that may be employed as a surrogate for iC3b based on an analogous response to multi-Fc therapeutics. The present invention further provides for improvements in the use of such multi-Fc therapeutics in the treatment of autoimmune and inflammatory diseases.

Abstract: The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc?Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.

Abstract: The present disclosure involves optimized methods for production of hiologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.

Abstract: In a method for the precipitation of particles of a metal carbonate material comprising nickel and manganese in an atomic ratio of 0?Ni:Mn?1:3, aqueous solutions comprising sulfates or nitrates of nickel and manganese are mixed with aqueous solutions of carbonates or mixtures of carbonates and hydroxides of sodium or potassium in a stirred reactor at pH>7.5 without the use of a chelating agent. Thereby agglomerated particles are formed without any subsequent process steps, in particular no subsequent process at temperatures higher than the precipitation temperature.

Abstract: The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc?Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

Abstract: An adhesive wafer for an ostomy device, the wafer comprising a skin-facing adhesive layer, a backing layer on a part of the non-skin-facing side of the adhesive layer, and a hole for accommodating a stoma. On the central portion of the wafer is located a release layer being configured to release a neutralizer. The release layer is in direct contact with the adhesive layer. The neutralizer is capable of neutralizing or at least minimizing the level of skin or adhesive aggressiveness of the output.

Abstract: The present disclosure involves biologically active proteins termed cysteine-optimized multimerizing stradomers. Thus, the present disclosure provides compositions and methods providing anti-autoimmune and anti-inflammatory activities, useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases.

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.